Denali's registration statement declared effective, extraordinary meeting scheduled.

• Denali's S-4 registration statement effective by SEC • Extraordinary general meeting on Sept. 3, 2025, at 9:00 a.m. ET • Post-closing company to be renamed "Semnur Pharmaceuticals, Inc." • Scilex focuses on non-opioid pain management products • Business combination aims to acquire, develop, and commercialize products • Scilex's revenue-generating strategy targets acute and chronic pain, neurodegenerative, and cardiometabolic diseases.

Scilex Holding Company (Nasdaq: SCLX) has announced a significant milestone in its corporate restructuring with the SEC's effectiveness declaration for its Form S-4 registration statement [1]. The statement pertains to the proposed business combination between Denali Capital Acquisition Corp. (OTCB: DNQAF) and Semnur Pharmaceuticals, Scilex's majority-owned subsidiary. The extraordinary general meeting for Denali shareholders is scheduled for September 3, 2025, at 9:00 a.m. ET in New York [1].

The effective S-4 registration statement clears a critical regulatory hurdle, paving the way for the September 3rd shareholder vote. Upon completion, the combined entity will be renamed to Semnur Pharmaceuticals, Inc. The application for Nasdaq listing has been submitted, but approval remains pending. If not approved, the combined company will continue trading on the OTC Markets, which typically offers less liquidity and visibility than national exchanges [1].

Scilex, an innovative revenue-generating company, focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain, neurodegenerative, and cardiometabolic diseases [2]. The business combination aims to create a more focused entity around Semnur's operations, potentially providing Scilex with capital and/or ongoing equity participation in the spun-off business [1].

Key uncertainties for investors include the pending Nasdaq listing application and the potential impact on Scilex's financial profile. The restructuring will alter Scilex's asset composition, but the precise economic implications depend on undisclosed details of the transaction structure [1].

For more information, refer to the SEC's website or contact Scilex Holding Company directly.

References:
[1] https://www.stocktitan.net/news/SCLX/scilex-holding-company-nasdaq-sclx-announces-effectiveness-of-lgdeumbkfnsy.html
[2] https://www.scilexholding.com